Appointment of Dr. Kalpesh Barot, MD Completes Phase One of ADIA Nutrition’s Medical Division
September 24, 2024 10:00 ET
|
ADIA Nutrition
WINTER PARK, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- ADIA Nutrition (OTC Pink: ADIA) is excited to announce the completion of its Board of Medical Directors with the appointment of Dr. Kalpesh...
ADIA Nutrition Stakes Claim in $6.7B Industry with Strategic Trademark Expansion
September 17, 2024 10:00 ET
|
ADIA Nutrition
WINTER PARK, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADIA Nutrition Inc. (OTC Pink: ADIA) has announced the hiring of a prominent Winter Springs law firm to fortify its intellectual property...
ADIA Nutrition Appoints Dr. Richard Edwards, DO as Second Medical Director
September 10, 2024 10:00 ET
|
ADIA Nutrition
WINTER PARK, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition (OTC Pink: ADIA) is excited to announce the appointment of Dr. Richard Edwards, DO, as its second Medical Director. Dr. Edwards...
Tiziana Life Sciences Appoints New Chief Executive Officer
August 19, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Tiziana Life Sciences Granted FDA Fast Track Designation
July 24, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis
July 16, 2024 08:37 ET
|
Trethera Corporation
LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
June 11, 2024 08:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
June 06, 2024 09:00 ET
|
Tiziana Life Sciences Ltd.
Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months.FDA...
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
May 30, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Bragar Eagel & Squire, P.C. Is Investigating Zoetis, and Morgan Stanley and Encourages Investors to Contact the Firm
May 07, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zoetis Inc. (NYSE: ZTS),...